KR101969515B1 - 재조합 vwf의 투여에 의한 응고 질환의 치료 - Google Patents

재조합 vwf의 투여에 의한 응고 질환의 치료 Download PDF

Info

Publication number
KR101969515B1
KR101969515B1 KR1020147000709A KR20147000709A KR101969515B1 KR 101969515 B1 KR101969515 B1 KR 101969515B1 KR 1020147000709 A KR1020147000709 A KR 1020147000709A KR 20147000709 A KR20147000709 A KR 20147000709A KR 101969515 B1 KR101969515 B1 KR 101969515B1
Authority
KR
South Korea
Prior art keywords
rvwf
composition
fviii
administered
vwf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147000709A
Other languages
English (en)
Korean (ko)
Other versions
KR20140039285A (ko
Inventor
프리드리히 샤이플링거
페터 투레첵
브루스 에웬스타인
윙 옌 웡
토비아스 엠 주이터
Original Assignee
박스알타 인코퍼레이티드
박스앨타 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박스알타 인코퍼레이티드, 박스앨타 게엠베하 filed Critical 박스알타 인코퍼레이티드
Publication of KR20140039285A publication Critical patent/KR20140039285A/ko
Application granted granted Critical
Publication of KR101969515B1 publication Critical patent/KR101969515B1/ko
Assigned to 다케다 야쿠힌 고교 가부시키가이샤 reassignment 다케다 야쿠힌 고교 가부시키가이샤 권리의 전부이전등록 Assignors: 박스알타 인코퍼레이티드, 박스앨타 게엠베하
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147000709A 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료 Active KR101969515B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US61/495,884 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US61/511,901 2011-07-26
US201161523790P 2011-08-15 2011-08-15
US61/523,790 2011-08-15
PCT/US2012/041957 WO2012171031A1 (en) 2011-06-10 2012-06-11 Treatment of coagulation disease by administration of recombinant vwf

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197010327A Division KR20190041032A (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료

Publications (2)

Publication Number Publication Date
KR20140039285A KR20140039285A (ko) 2014-04-01
KR101969515B1 true KR101969515B1 (ko) 2019-04-16

Family

ID=46321496

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020147000709A Active KR101969515B1 (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료
KR1020197010327A Ceased KR20190041032A (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료
KR1020207020667A Active KR102319868B1 (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197010327A Ceased KR20190041032A (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료
KR1020207020667A Active KR102319868B1 (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료

Country Status (23)

Country Link
US (3) US9272021B2 (https=)
EP (3) EP3412305B1 (https=)
JP (3) JP6347468B2 (https=)
KR (3) KR101969515B1 (https=)
CN (3) CN108210889A (https=)
AR (1) AR086904A1 (https=)
AU (5) AU2012267458A1 (https=)
CA (1) CA2838845C (https=)
DK (3) DK3412305T3 (https=)
ES (3) ES2976169T3 (https=)
FI (1) FI3858375T3 (https=)
HK (1) HK1257436A1 (https=)
HR (1) HRP20180962T1 (https=)
HU (1) HUE039317T2 (https=)
LT (1) LT2717905T (https=)
MX (2) MX350582B (https=)
PL (3) PL2717905T3 (https=)
PT (3) PT3412305T (https=)
RU (2) RU2628537C2 (https=)
SG (2) SG10202002591QA (https=)
SI (1) SI2717905T1 (https=)
TR (1) TR201808823T4 (https=)
WO (1) WO2012171031A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3412305T3 (da) * 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
CA3020346A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
KR102788331B1 (ko) 2017-07-07 2025-03-27 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf의 투여에 의해 대기 수술을 받은 중증 폰 빌레브란트 병을 가지고 있는 환자의 치료
EP4424366A3 (en) 2017-07-07 2024-12-04 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
EP3749696A1 (en) 2018-02-06 2020-12-16 Ablynx N.V. Methods of treating initial episode of ttp with immunoglobulin single variable domains
IL277464B1 (en) * 2018-03-21 2026-04-01 Baxalta Inc Separation of VWF and VWF propeptide using chromatographic methods
EA202192140A1 (ru) * 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
CN114929260A (zh) * 2019-09-11 2022-08-19 武田药品工业株式会社 与冯维勒布兰德因子和补体c1q的复合物相关的治疗方法
CN115335074A (zh) * 2020-02-04 2022-11-11 武田药品工业株式会社 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多
TW202237149A (zh) * 2020-11-24 2022-10-01 美商邦德治療公司 用於治療出血性障礙之組成物及方法
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009086400A2 (en) 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
EP0218692A4 (en) 1985-04-11 1988-03-22 Childrens Medical Center VON WILLEBRAND FACTOR.
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CN101163506B (zh) * 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用
KR20100095441A (ko) 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
PL2291523T3 (pl) * 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
EP2349314B1 (en) * 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
AU2010279463A1 (en) * 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
WO2012006594A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
DK3412305T3 (da) * 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009086400A2 (en) 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Schlokat U., Biotechnol. Appl. Biochem. 1996, 제24권, 제257-267면.
Turecek, P.L., Seminars in Thrombosis and Hemostasis, 2010, 제36권 제5호 제510-521면

Also Published As

Publication number Publication date
PT2717905T (pt) 2018-07-02
KR20200091476A (ko) 2020-07-30
PL3858375T3 (pl) 2024-05-20
EP2717905A1 (en) 2014-04-16
AU2012267458A1 (en) 2014-01-09
AU2016202299B2 (en) 2017-07-20
LT2717905T (lt) 2018-10-10
JP2017019788A (ja) 2017-01-26
CA2838845A1 (en) 2012-12-13
AU2022201518A1 (en) 2022-03-24
EP3412305B1 (en) 2021-01-06
JP6347468B2 (ja) 2018-06-27
KR20190041032A (ko) 2019-04-19
RU2019103386A (ru) 2020-08-07
SG10202002591QA (en) 2020-05-28
US20120316116A1 (en) 2012-12-13
JP2019048892A (ja) 2019-03-28
DK2717905T3 (en) 2018-07-02
US20250387455A1 (en) 2025-12-25
PL3412305T3 (pl) 2021-05-31
AR086904A1 (es) 2014-01-29
ES2682249T3 (es) 2018-09-19
EP2717905B1 (en) 2018-05-23
AU2017206235A1 (en) 2017-08-03
SG10201604684WA (en) 2016-07-28
TR201808823T4 (tr) 2018-07-23
AU2016202299A1 (en) 2016-05-05
JP6527114B2 (ja) 2019-06-05
MX2020000083A (es) 2020-08-06
EP3858375B1 (en) 2024-03-20
AU2022201518B2 (en) 2025-07-03
PT3412305T (pt) 2021-01-29
DK3412305T3 (da) 2021-03-01
BR112013031795A2 (pt) 2016-12-20
HRP20180962T1 (hr) 2018-10-19
CA2838845C (en) 2019-08-06
CN103732244A (zh) 2014-04-16
RU2680402C2 (ru) 2019-02-21
ES2860450T3 (es) 2021-10-05
KR102319868B1 (ko) 2021-11-01
EP3858375A1 (en) 2021-08-04
MX350582B (es) 2017-09-11
US9272021B2 (en) 2016-03-01
US20160184403A1 (en) 2016-06-30
RU2014100107A (ru) 2015-07-20
AU2017206235B2 (en) 2019-10-17
MX2013014543A (es) 2014-06-11
SI2717905T1 (sl) 2018-09-28
PL2717905T3 (pl) 2018-10-31
DK3858375T3 (da) 2024-04-15
HUE039317T2 (hu) 2018-12-28
FI3858375T3 (fi) 2024-04-17
RU2017102679A (ru) 2018-12-19
CN107412743A (zh) 2017-12-01
RU2017102679A3 (https=) 2018-12-19
JP2014516088A (ja) 2014-07-07
ES2976169T3 (es) 2024-07-24
EP3412305A1 (en) 2018-12-12
CN108210889A (zh) 2018-06-29
PT3858375T (pt) 2024-04-18
AU2020200026A1 (en) 2020-01-30
HK1257436A1 (zh) 2019-10-18
KR20140039285A (ko) 2014-04-01
RU2628537C2 (ru) 2017-08-18
NZ618790A (en) 2015-07-31
CN107412743B (zh) 2021-07-02
RU2019103386A3 (https=) 2022-01-24
WO2012171031A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
KR101969515B1 (ko) 재조합 vwf의 투여에 의한 응고 질환의 치료
JP7641327B2 (ja) 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
JP7326246B2 (ja) 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
CN113645993A (zh) 使用重组VWF(rVWF)进行预防性治疗的方法
HK40056758A (en) Treatment of coagulation disease by administration of recombinant vwf
HK40056758B (en) Treatment of coagulation disease by administration of recombinant vwf
BR112013031795B1 (pt) Uso de fator de von willebrand recombinante (rvwf)
JP2023514541A (ja) 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療
HK40064201A (en) Methods of prophylactic treatment using recombinant vwf (rvwf)
HK40001633A (en) Treatment of coagulation disease by administration of recombinant vwf
HK40001633B (en) Treatment of coagulation disease by administration of recombinant vwf
HK40031159A (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
HK1196768B (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768A (en) Treatment of coagulation disease by administration of recombinant vwf

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140110

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20160422

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180313

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181010

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180313

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20181010

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180611

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170224

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20190110

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20181220

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20181010

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20180611

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170224

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190410

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190410

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190411

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20220324

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20220324

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230323

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240401

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20250324

Start annual number: 7

End annual number: 7